Pretomanid in the Treatment of Patients with Tuberculosis in the United States

N Engl J Med. 2022 Sep 1;387(9):850-852. doi: 10.1056/NEJMc2119461.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antitubercular Agents* / therapeutic use
  • Humans
  • Mycobacterium tuberculosis*
  • Nitroimidazoles* / adverse effects
  • Nitroimidazoles* / therapeutic use
  • Tuberculosis* / drug therapy
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • United States

Substances

  • Antitubercular Agents
  • Nitroimidazoles
  • pretomanid